Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis
Scientific Reports, 2020
Magis A., Rappaport N., Conomos M., Omenn G., Lovejoy J., Hood L., Price N.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology Wider Proteomics Studies | Patient Stratification | Plasma |  Olink Target 96 |
Abstract
We analyzed 1196 proteins in longitudinal plasma samples from participants in a commercial wellness program, including samples collected pre-diagnosis from ten cancer patients and 69 controls. For three individuals ultimately diagnosed with metastatic breast, lung, or pancreatic cancer, CEACAM5 was a persistent longitudinal outlier as early as 26.5 months pre-diagnosis. CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 levels spiked in metastatic breast cancer between 10.0 and 4.0 months pre-diagnosis. Our results support the value of deep phenotyping seemingly healthy individuals in prospectively inferring disease transitions.